Zydus receives final approval for Clonidine Hcl Injection

24 Feb 2014 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drugs Administration (USFDA) to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml. Clonidine hydrochloride injection is a centrally-acting analgesic solution for use in continuous epidural infusion devices which is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. The group now has 90 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.

Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×